A local study, a part of a multinational and multicenter study on the efficacy and safety of Buserelin was carried out for the treatment ofpelvic endometriosis using a standard protocol. 20 women diagnosed to have moderate to severe endometriosis by laparoscopy were recruited. The women were given 900 micrograms Buserelin acetate daily by intranasal spray for a fixed period of 6 months. 8aseline hormona/and biochemical parameters were taken prior to treatment and the parameters were repeated during each follow-up at weekly and monthly intervals. In addition. changes in
symptoms were monitored. A second look laparoscopy was performed at completion of therapy and patients were followed up for a further 6 months. There was 100 percent suppression of oestradiol levels dUring the 6 months treatment period. An improvement of implants according to AFS classification occured in all patients. One patient discontinued because of side effects. Restoration of cycles after completion of therapy occured within 7 weeks. There were 7 pregnancies (64%) in the first 6 months after treatment for those wanting pregnancies. During therapy, dysmenorrhoea, pelvic pain and dyspareunia improved ,considerably. Buserelin was proven to be effective in the management of pelvic endometriosis a.~d is well tolerated and safe.